Alzheimer's disease (AD) stands as a prevailing neurodegenerative condition (NDs), leading to the gradual deterioration of brain cells and subsequent declines in memory, thinking, behavior, and emotion.
New research heightened light sensitivity in Alzheimer's patients to "sundowning," a worsening of symptoms late in the day, and sleep disruptions that may advance the disease.
Those who snore can be aging their brains by years and hurting their brain health by depriving themselves of getting deep sleep, according to researchers with the Faculty of Medicine at the University of Paris-Cité, Paris, France.
Around 6 million people in the U.S. currently live with Alzheimer's disease. By 2050, this figure is projected to increase to almost 13 million.
Scientists have long known that the loss of olfactory capacity, or ability to smell, can predict development of nearly 70 neurological and psychiatric diseases. These include Alzheimer's and other dementias, Parkinson's, schizophrenia and alcoholism. Evidence is emerging about a link between smell loss due to COVID and ensuing cognitive decrease....
Phyllodulcin, a natural sweetener found in Hydrangea macrophylla var. thunbergii, shows potential for treating Alzheimer's disease (AD).
An article published in the journal Lancet Neurology evaluates the risk of recurrence of active disease in older patients with multiple sclerosis after discontinuing disease-modifying therapies.
Seniors who took low-dose aspirin daily for primary prevention had no reduction in the risk for first strokes in a large randomized trial that followed them for about 5 years (Daily Aspirin Challenged in Primary Stroke Prevention: ASPREE).
Is myocardial infarction (MI) associated with cognition acutely after MI or in the years following MI?
Solanezumab, a monoclonal antibody that binds to the monomeric or soluble form of amyloid-beta, is no better than placebo in slowing the progression of preclinical Alzheimer's disease (AD), results of a phase 3 trial show.
